Raymond James Started Five Prime Therapeutics (NASDAQ:FPRX) Coverage On Jun 29, 2018.

June 29, 2018 - By Noel Courtney

Big Money Sentiment increased to 2.33 in 2018 Q1. It has change of 0.99, from 2017Q4’s 1.34. The ratio improved due to Five Prime Therapeutics, Inc. positioning: 21 sold and 12 reduced. 21 funds acquired positions and 56 increased positions. Investors holded 25.47 million in 2017Q4 but now own 31.62 million shares or 24.14% more.

Jacobs Levy Equity Mgmt Inc has 27,990 shs for 0.01% of their capital. Spark Invest Management Ltd, a New York-based fund reported 12,100 shs. Manufacturers Life Ins Com The has invested 0% in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). 977,500 are owned by Bb Biotech Ag. Moreover, Marshall Wace Limited Liability Partnership has 0.01% invested in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). Dimensional Fund L P has 1.04 million shs. State Of Wisconsin Board invested 0% in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). Secor Cap Advisors Ltd Partnership accumulated 0.03% or 23,236 shs. Los Angeles Cap Equity Rech Inc invested 0% of its capital in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). 369,200 are held by Renaissance Technology Ltd. Dupont Cap Mngmt Corp owns 25,152 shs. Tiaa Cref Invest Management Ltd Com reported 73,270 shs. Bancorp Of Mellon has invested 0% in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). Schwab Charles Investment Inc invested 0% in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). Alps Advisors accumulated 0.01% or 45,616 shs.

What’s Raymond James’s Current Rate of Five Prime Therapeutics (NASDAQ:FPRX)

On Thursday morning was set Five Prime Therapeutics (NASDAQ:FPRX)‘s “Market Perform” rating by Stock analysts and Raymond James initiated coverage on FPRX.

Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Ratings Coverage

Total analysts of 8 have positions in Five Prime Therapeutics (NASDAQ:FPRX) as follows: 4 rated it a “Buy”, 0 with “Sell” and 4 with “Hold”. The positive are 50%. Since February 15, 2018 according to StockzIntelligence Inc Five Prime Therapeutics has 8 analyst reports. On Wednesday, February 28 the rating was maintained by BMO Capital Markets with “Outperform”. On Thursday, February 15 Guggenheim maintained Five Prime Therapeutics, Inc. (NASDAQ:FPRX) rating. Guggenheim has “Buy” rating and $30.0 target. On Wednesday, February 28 the rating was maintained by Nomura with “Buy”. The company rating was maintained by Jefferies on Thursday, March 1.

The stock increased 0.39% or $0.06 during the last trading session, hitting $15.61.Five Prime Therapeutics, Inc. has volume of 110,090 shares. Since June 29, 2017 FPRX has declined 37.93% and is downtrending. The stock underperformed the S&P500 by 50.50%.

On August, 14 Five Prime Therapeutics, Inc. (NASDAQ:FPRX)’s earnings release is anticipated by WallStreet, as reported by RTT. This year’s earnings per share analyst estimate is anticipated to be $-1.45. That is 8.23 % up compareed to $-1.58 earnings per share for last year. Last quarter $-0.63 earnings per share was reported. Analysts sees 130.16 % negative EPS growth this quarter.

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics.The company has $549.62 million market cap. The company's product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor.Last it reported negative earnings. The Company’s product candidates also comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor IIb, which is in Phase I clinical trials to treat patients with gastric or gastroesophageal junction and bladder cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 as a monotherapy in various cancers.

For more Five Prime Therapeutics, Inc. (NASDAQ:FPRX) news published recently go to: Businesswire.com, Streetinsider.com, Benzinga.com, Benzinga.com or Benzinga.com. The titles are as follows: “Five Prime Therapeutics to Present at Goldman Sachs 39th Annual Global Healthcare Conference” published on June 05, 2018, “JPMorgan Starts Five Prime Therapeutics (FPRX) at Neutral” on June 15, 2018, “Benzinga’s Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos” with a publish date: June 29, 2018, “Benzinga’s Daily Biotech Pulse: Clinical Hold For Crispr, Gilead Study Meets Endpoint, Akers Gets Grace Time” and the last “Benzinga’s Top Upgrades, Downgrades For June 15, 2018” with publication date: June 15, 2018.

Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.